BIVIW — BIOVIE INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1580149 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -5,649,932 | -5,605,070 | 11,037,959 | 7,732,817 | 4,509,301 |
| Jun 2026 | 0 | — | -5,719,456 | -5,645,532 | 14,250,462 | 8,977,370 | 3,980,192 |
| Mar 2026 | 0 | — | -5,385,377 | -5,270,299 | 17,514,621 | 13,098,976 | 1,907,029 |
| Dec 2025 | 0 | — | -6,262,305 | -6,069,475 | 22,503,293 | 20,540,585 | 3,238,259 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,024,806
Investing CF
$0
Financing CF
$10,457,629
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-374,260,653
Inventory
—
Receivables
$2,151,440
ST Investments
—
EBIT TTM
$-22,054,962
Pretax Income TTM
$-22,072,863
Interest Exp TTM
$17,901
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | -22,651,733 | -22,072,863 | 14,250,462 | 3,980,192 | 10,270,270 | -19,024,806 |
| Jun 2025 | 0 | -18,066,200 | -17,542,120 | 21,562,199 | 2,550,214 | 19,011,985 | -19,025,205 |
| Jun 2024 | 0 | -32,179,585 | -32,120,533 | 25,208,345 | 9,702,130 | 15,506,215 | -27,945,024 |
| Jun 2023 | 0 | -45,080,448 | -50,255,815 | 35,104,730 | 19,764,444 | 15,340,286 | -40,252,881 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-22,072,863
OpCashFlow TTM
—
Assets (Latest)
$17,514,621
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
BioVie says bezisterim shows distinct responses in two Long COVID patient groups
2026-11-16 14:57 · Yahoo
BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026
2026-11-16 13:00 · Yahoo
BioVie to present additional Parkinson’s drug data at international conference
2026-11-10 14:32 · Yahoo
BioVie Invited to Present Data on Bezisterim in Parkinson’s Disease at the AD/PD2027 International Conference on Alzheimer's & Parkinson’s Diseases
2026-11-10 13:00 · Yahoo
BioVie identifies two Long COVID patient groups with distinct responses to bezisterim
2026-11-09 14:28 · Yahoo
BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop
2026-11-09 13:00 · Yahoo
Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg Television
2026-11-07 17:05 · Yahoo
BioVie to raise $4.74 million in registered direct offering
2026-11-04 14:01 · Yahoo
BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
2026-11-04 13:00 · Yahoo
BioVie to present new Long COVID biomarker data at Nice conference
2026-11-02 14:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.